New Jersey A 5101: Requires public members of Drug Utilization Review Board to disclose financial interests and benefits received from and investment interests held in pharmaceutical manufacturers.

Status: Introduced in the Assembly, Referred to Assembly Health and Senior Services Committee (as of 2019-03-05)

State: New Jersey · Session: 218 · Bill: A 5101

Subjects: PHARMACEUTIC

Sponsors: Armato, John, Karabinchak, Robert J.

View New Jersey A 5101 on LegisTrack → — full text, sponsors, votes, campaign finance, and cross-state matches.